Table 1. Patient characteristics and response to prior therapies.

Characteristics	Total (n=18)
Age—yr
Median	57
Range	45–78
Sex—n (%)
Male	9 (50.0)
Female	9 (50.0)
Race—n (%)
White	17 (94.4)
Black	1 (5.6)
Histology—n (%)
Adenocarcinoma	9 (50.0)
Squamous cell	2 (11.1)
NSCLC, NOSa	7 (38.9)
Performance Status—n (%)
0	5 (27.8)
1	12 (66.7)
2	1 (5.6)
Disease stage—n (%)
Metastatic	16 (88.9)
Recurrent	2 (11.1)
Brain metastases—n (%)	6 (33.3)
Prior first-line systemic therapy—n (%)
Paclitaxel/Platinum	10 (55.5)
Paclitaxel/Platinum/Bevacizumab	2 (11.1)
Paclitaxel/Platinum/Investigational drug	2 (11.1)
Pemetrexed/Platinum	3 (16.7)
Vinorelbine/Platinum	1 (5.6)
Response to first-line therapy—n (%)
Partial response	7 (38.9)
Stable disease	4 (22.2)
Progressive disease	6 (33.3)
Not reported	1 (5.6)
Prior second-line systemic therapy—n (%)
Pemetrexed	10 (55.5)
Pemetrexed/Investigational drug	1 (5.6)
Docetaxel/Investigational drug	1 (5.6)
Erlotinib	4 (22.2)
Platinum doublets	2 (11.1)
Response to second-line therapy—n (%)
Partial response	1 (5.6)
Stable disease	3 (16.7)
Progressive disease	13 (72.2)
Not reported	1 (5.6)
Prior thoracic radiation therapy—n (%)	6 (33.3)

^aNSCLC, NOS, non-small cell lung cancer, not otherwise specified